A Letter from our President

Although the DSCSA deadline has been extended, Camber has been ready for over a year. You can read more about it in a recent letter from Camber’s president to our customers. You can learn more about how Camber has prepared at our DSCSA Compliance Page.
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection